Cardiological monitoring during BTK inhibitor, ICI, and RAF/MEK inhibitor therapy: the single-center prospective Registry for Cardiovascular Events under new cancer Therapies (RECENT)

Katharina Seuthe (Köln)1, F. Simon (Köln)2, C. Hohmann (Köln)1, N. Kutsch (Köln)2, P. Bröckelmann (Köln)2, N. Kreuzberg (Köln)3, P. Paffenholz (Köln)4, L. Nachtsheim (Köln)5, A. Tuchscherer (Köln)2, U. Mons (Köln)1, M. Hallek (Köln)2, S. Baldus (Köln)1, B. Eichhorst (Köln)2, R. Pfister (Köln)1

1Herzzentrum der Universität zu Köln Klinik III für Innere Medizin Köln, Deutschland; 2Uniklinik Köln Medizinische Klinik I Köln, Deutschland; 3Uniklinik Köln Klinik und Poliklinik für Dermatologie und Venerologie Köln, Deutschland; 4Uniklink Köln Klinik für Urologie Köln, Deutschland; 5Uniklinik Köln Klinik und Poliklinik für Hals-, Nasen- und Ohrenheilkunde Köln, Deutschland



The advent of novel targeted cancer therapies, such as Bruton's tyrosine kinase (BTK) inhibitors, immune checkpoint inhibitors (ICI), and RAF/MEK inhibitors, have revolutionized cancer treatment. However, concerns about their impact on cardiovascular health persist and recent guidelines recommend cardiac monitoring. Yet, prospective data on incidence rates of cardiovascular events are lacking. The Registry for Cardiovascular Events under new cancer Therapies (RECENT) aims to systematically assess clinical as well as subclinical cardiovascular incidents in patients undergoing these novel cancer therapies to identify baseline risk factors and derive individualized monitoring strategies.



This ongoing single-center prospective registry enrolls cancer patients receiving BTK inhibitors, ICI, or RAF/MEK inhibitors. Baseline cardiovascular assessment, risk stratification according to HFA-ICOS risk score, and follow up visits for 12 months at three-monthly intervals (including ECG, biomarkers and echocardiography) during treatment are conducted. Treatment-related events, in particular hypertension, arrhythmias, cancer therapy-related cardiac dysfunction (CTRCD), and (peri-) myocarditis, as defined according to current guideline recommendations, are recorded.



We report data of the first 85 patients (60.9 ± 14.7 years, 52.9% male) included in this ongoing registry. Of those, 17/85 patients received treatment with BTK inhibitors (20%), 45/85 with ICI (53%) and 23/85 with RAF/MEK inhibitors (27%). Most common treatment indications were dermatological (39/85, 45.9%), hematologic (17/85, 20%), urological (13/85, 15.3%) and head and neck (11/85, 12.9%) cancers. Before treatment, the majority of patients were stratified as low-risk (31/85) or moderate-risk (32/85), and 22/85 (25.9%) as high-risk.

7/85 (8.2%) patients were newly diagnosed with cardiovascular disease at baseline visit, resulting in a change in risk category and subsequent initiation of cardiovascular treatment. This includes 3 patients who had been initially categorized as low-risk and would not have been referred for further cardiac workup due to current guideline recommendations.

The six months follow up visit has been completed in 44/85 patients. Among these, 1/20 patients (5%) with ICI developed a perimyocarditis and 2/11 patients (18.2%) with BTK inhibitors developed atrial fibrillation. 1/13 patients (7.7%) with RAF/MEK inhibitor therapy, classified as low-risk at baseline, developed asymptomatic CTRCD, which resolved after initiation of cardioprotective drug therapy.



Novel cancer therapies affect cardiovascular health. This interim analysis of the RECENT registry indicates benefit of a structured baseline cardiac assessment prior to cancer treatment in all patients, irrespective of the initial risk stratification. Contrary to current guidelines which recommend echocardiographic monitoring in patients receiving RAF/MEK inhibitors only in high-risk patients, the current data advocate for extending this also to low-risk patients to detect subclinical deterioration of the cardiovascular status.   

Diese Seite teilen